| abstract |
The combination is used to treat diabetes mellitus (diabetes mellitus), in particular type 2 diabetes, and conditions related to diabetes mellitus. The combination includes from 2 to 8 mg of 5- [4- [2- (N-methyl-N- (2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione (Compound I) or its tautomeric form, or a pharmaceutically acceptable derivative thereof as an insulin sensitizer, and a sulfonylurea. |